AKR1C3 is an aldo–keto reductase that has been described as responsible for gaining resistance against cisplatin treatment when overexpressed in colon cancer cells together with AKR1C1[Gene ID: 1645] [44]. The gene discussed is AKR1C3; the disease is malignant colon neoplasm.